McNicoll, Lewis & Vlak Lowers SuperGen PT, Maintains Buy

McNicoll, Lewis & Vlak lowered its SuperGen SUPG price target from $8 to $6.50 and maintained its SuperGen Buy rating in a research report published today. In the report, McNicoll, Lewis & Vlak states, "We expect significant changes in SuperGen's pipeline following a portfolio review now underway, as well as further restructuring. We also expect a substantial increase in operating expenses following full integration of Astex by SuperGen, which compels us to lower our one-year target price to $6.50 (from $8.00) while maintaining our BUY recommendation." Shares of SuperGen were trading at $2.69 at the time of posting, down 4.27% from Wednesday's market close.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsHealth CareLewis & VlakMcNicollPharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!